Evrofarma (Greece) Performance
| EVROF Stock | EUR 3.94 0.04 1.03% |
On a scale of 0 to 100, Evrofarma holds a performance score of 23. The firm shows a Beta (market volatility) of -1.0, which means a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Evrofarma are expected to decrease slowly. On the other hand, during market turmoil, Evrofarma is expected to outperform it slightly. Please check Evrofarma's treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Evrofarma's price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Evrofarma SA are ranked lower than 23 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Evrofarma sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Price Earnings Ratio | 10.6329 | |
| Total Cashflows From Investing Activities | -3.3 M |
Evrofarma |
Evrofarma Relative Risk vs. Return Landscape
If you would invest 258.00 in Evrofarma SA on October 11, 2025 and sell it today you would earn a total of 132.00 from holding Evrofarma SA or generate 51.16% return on investment over 90 days. Evrofarma SA is generating 0.7454% of daily returns and assumes 2.5049% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than Evrofarma, and 85% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Evrofarma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evrofarma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evrofarma SA, and traders can use it to determine the average amount a Evrofarma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2976
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EVROF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.5 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.75 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.3 actual daily | 23 77% of assets perform better |
Based on monthly moving average Evrofarma is performing at about 23% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evrofarma by adding it to a well-diversified portfolio.
Evrofarma Fundamentals Growth
Evrofarma Stock prices reflect investors' perceptions of the future prospects and financial health of Evrofarma, and Evrofarma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evrofarma Stock performance.
| Return On Equity | -0.0792 | |||
| Return On Asset | -0.0024 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 33.15 M | |||
| Shares Outstanding | 13.67 M | |||
| Price To Earning | 13.89 X | |||
| Price To Sales | 0.26 X | |||
| Revenue | 38.81 M | |||
| EBITDA | 1.28 M | |||
| Cash And Equivalents | 554 K | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 18.45 M | |||
| Debt To Equity | 158.30 % | |||
| Book Value Per Share | 0.92 X | |||
| Cash Flow From Operations | (805 K) | |||
| Earnings Per Share | 0.08 X | |||
| Total Asset | 44 M | |||
| Retained Earnings | (3 M) | |||
| Current Asset | 14 M | |||
| Current Liabilities | 13 M | |||
About Evrofarma Performance
By analyzing Evrofarma's fundamental ratios, stakeholders can gain valuable insights into Evrofarma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Evrofarma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Evrofarma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
It offers milk and liquids, ayran, cheese and organic cheese, and yogurt. EVROFARMA is traded on Athens Stock Exchange in Greece.Things to note about Evrofarma SA performance evaluation
Checking the ongoing alerts about Evrofarma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evrofarma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evrofarma SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 38.81 M. Net Loss for the year was (355 K) with profit before overhead, payroll, taxes, and interest of 3.84 M. | |
| Evrofarma SA has accumulated about 554 K in cash with (805 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 76.0% of the company shares are held by company insiders |
- Analyzing Evrofarma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evrofarma's stock is overvalued or undervalued compared to its peers.
- Examining Evrofarma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evrofarma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evrofarma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evrofarma's stock. These opinions can provide insight into Evrofarma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Evrofarma Stock analysis
When running Evrofarma's price analysis, check to measure Evrofarma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evrofarma is operating at the current time. Most of Evrofarma's value examination focuses on studying past and present price action to predict the probability of Evrofarma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evrofarma's price. Additionally, you may evaluate how the addition of Evrofarma to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |